当前位置: 首页 > 期刊 > 《临床心身疾病杂志》 > 2006年第2期
编号:11024912
米氮平与文拉法辛治疗抑郁症对照研究
http://www.100md.com 《临床心身疾病杂志》 2006年第2期
米氮平;,文拉法辛;,抑郁症,,米氮平;,文拉法辛;,抑郁症,【摘要】,【关键词】,1对象与方法,2结果,3讨论,参考文献
     【摘要】 目的 探讨米氮平与文拉法辛治疗抑郁症的疗效与不良反应。方法 将100例抑郁症患者随机分为米氮平组和文拉法辛组。于治疗1,2,6w末采用汉密尔顿抑郁量表和副反应量表评定临床疗效与不良反应。 结果 治疗2w末时,文拉法辛组减分率较米氮平组下降明显,差异有显著性(t=2.61,P<0.05);治疗6w末两组减分率无显著性差异(t=0.21,P>0.05)。治疗结束时米氮平组显效率64%,有效率88%;文拉法辛组显效率60%,有效率80%,两组疗效无显著性差异。两组不良反应均较轻微,且差异无显著性(P>0.05)。结论 米氮平与文拉法辛的抗抑郁疗效肯定,不良反应轻微。

    【关键词】 米氮平; 文拉法辛; 抑郁症

    Controlled study of mirtazapine vs. venlafaxine in the treatment of depression

    Wu Yubo

    (The 3rd People's Hospital of Heze, Shandong,China)

    【Abstract】 Objective To explore efficacies and side effects of mirtazapine vs. venlafaxine in the treatment of depression. Methods 100 patients with depression were randomly divided into mirtazapine and venlafaxine group. Efficacies and side effects were assessed with the Hamilton Depression Scale(HADS) and Treatment Emergent Symptom Scale(TESS) at the ends of the 1st, 2nd and 6th week of treatment. Results At the end of the 2nd week, scorereducing rate decreased more significantly in the venlafaxine than in the mirtazapine group, and difference was significant(P<0.05); at the end of the 6th week, there was no significant difference in scorereducing rate between the 2 groups(P>0.05).After treatment, effectual and effective rates of the mirtazapine group were 64% and 88% and those of the venlafaxine 60% and 80% respectively, which showed no significant difference. Side effects of both 2 groups were milder and had no significant difference(P>0.05). Conclusion Both mirtazapine and venlafaxine have better efficacy and milder side effect in the treatment of depression. ......

您现在查看是摘要页,全文长 4598 字符